表紙
市場調査レポート

ホルモン置換療法の世界市場:2015〜2019年

Global Hormone Replacement Therapy Market 2015-2019

発行 TechNavio (Infiniti Research Ltd.) 商品コード 307863
出版日 ページ情報 英文 69 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.55円で換算しております。
Back to Top
ホルモン置換療法の世界市場:2015〜2019年 Global Hormone Replacement Therapy Market 2015-2019
出版日: 2015年11月11日 ページ情報: 英文 69 Pages
概要

ホルモン置換療法は、ホルモンレベルの低くなった閉経間近な女性、あるいは小人症などの成長ホルモン不全患者の体内でホルモンを置換します。2014年は米国が市場を独占し、今後もこの動向は続くものとみられていますが、アジア太平洋地域も急速に拡大しています。世界のホルモン置換療法市場は2019年までCAGR2%で緩やかに成長するとみられています。

当レポートでは、世界のホルモン置換療法市場について調査し、地域別動向、今後の市場成長見込み、2019年の市場規模予測、市場成長の課題、主要ベンダーの動向などをまとめています。

第1章 エグゼクティブサマリー

第2章 当レポートの範囲

第3章 市場調査方法

第4章 イントロダクション

第5章 市場環境

  • 市場概要
  • 市場規模と予測
  • ファイブフォース分析

第6章 ホルモン療法別市場セグメンテーション

  • エストロゲン
  • 成長ホルモン

第7章 投与ルート別市場セグメンテーション

  • 経口
  • 非経口
  • 経皮

第8章 世界のエストロゲン置換療法市場

  • 市場概要
  • 市場規模と予測

第9章 世界の成長ホルモン置換療法

  • 市場概要
  • 市場規模と予測

第10章 地域別セグメンテーション

  • 南北アメリカ
  • 欧州・中東・アフリカ
  • アジア太平洋地域

第11章 市場促進因子

  • アンメットニーズ
  • 技術の進歩
  • 承認済み薬剤の再調製
  • ライフスタイルの変化

第12章 促進因子の影響

第13章 市場の課題

  • 薬剤開発コストの高さ
  • 副作用
  • 保存問題
  • パイプラインの不備

第14章 促進因子と課題の影響

第15章 市場動向

  • 新規ドラッグデリバリーメカニズム
  • 非ホルモン療法へのパラダイムシフト
  • 合併・買収

第16章 ベンダー環境

  • 競合シナリオ
  • 新規ニュース
  • 合併・買収
  • 2014年の市場シェア分析
  • その他の注目すべきベンダー

第17章 主要ベンダー分析

  • F. Hoffmann-La Roche
  • Merck Serono
  • Novartis
  • Novo Nordisk

第18章 付録

第19章 Techvavioについて

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: IRTNTR7871

Covering: An in-depth study of the global hormone replacement therapy market and segmentation by type of hormonal therapy (estrogen replacement therapy and growth hormone replacement therapy), by route of administration (oral, parenteral, and transdermal), and by geography (the Americas, EMEA, and APAC). The report also presents the vendor landscape and a corresponding detailed analysis of the top vendors in the market, including F. Hoffmann-La Roche, Merck Serono, Novartis, Novo Nordisk, and Pfizer.

An overview of the hormone replacement therapy market

Hormone replacement therapy involves the replacement of the hormones in the body whose levels have become low, in case of women nearing menopause or patient with growth hormone deficiency due to conditions such as dwarfism. At present, the combination of drugs are used to treat the conditions, which are known to have a better safety and efficacy parameter. Unmet medical needs is one of the major drivers influencing the growth of the market. Therefore, the need for new treatment options with better safety results to accommodate the current unmet need is huge.

In 2014, the Americas dominated the market, where the majority of the contribution was from the US, and this trend is expected to continue during the forecast period. However, the market in the APAC region is witnessing a rapid growth, hence, there is a vast opportunity for vendors to venture into this region. Technavio expects the global hormone replacement therapy market to grow at a moderate rate, posting a CAGR of over 2% during the forecast period.

Segmentation of the hormone replacement therapy market by type of hormonal therapy

  • Estrogen replacement therapy
  • Growth hormone replacement therapy

With a market share of more than 60% the estrogen replacement therapy segment dominate the hormone replacement therapy market. Estrogen replacement therapy is a type of therapy in which estrogen hormones are commonly used to treat the symptoms of menopause. It helps in the reduction of short-term changes of menopause such as hot flashes, disturbed sleep, and vaginal dryness.

Segmentation of the hormone replacement therapy market by route of administration

  • Oral
  • Parenteral
  • Transdermal

The oral route of administration is a sub-division of enteral administration and is regarded as one of the safest and most preferred routes of drug administration. Some of the drug that are administered orally are Premarin and Estrace.

Competitive landscape and key vendors

The global hormone replacement therapy market is a mature market, which is extremely competitive due to the presence of a huge number of small and large vendors. Therefore, development of low-dose oral drugs and locally acting transdermal hormonal replacement products with high efficacy is expected to captivate the attention of players in the hormonal replacement market.

Key vendors in this market are -

  • F. Hoffmann-La Roche
  • Merck Serono
  • Novartis
  • Novo Nordisk
  • Pfizer

Other prominent vendors included in this report are Abbott Laboratories, Amgen, ANI Pharmaceuticals, Bayer, Eli Lilly, Hisamitsu Pharmaceutical, Ipsen, Merck, Mylan Laboratories, Orion, QuatRx Pharmaceuticals, Teva Pharmaceutical Industries, and TherapeuticsMD.

Key questions answered in the report include

  • What will the market size and the growth rate be in 2019?
  • What are the key factors driving the global hormone replacement therapy market?
  • What are the key market trends impacting the growth of the global hormone replacement therapy market?
  • What are the challenges to market growth?
  • Who are the key vendors in the global hormone replacement therapy market?
  • What are the market opportunities and threats faced by the vendors in the global hormone replacement therapy market?
  • What are the trending factors influencing the market shares of the Americas, EMEA, and APAC?
  • What are the key outcomes of the five forces analysis of the global hormone replacement therapy market?

Technavio also offers customization on reports based on specific client requirement.

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Top-vendor offerings

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights

PART 05: Market landscape

  • Market overview
  • Market size and forecast
  • Five forces analysis

PART 06: Market segmentation by type of hormonal therapy

  • Estrogen replacement therapy
  • Growth hormone replacement therapy

PART 07: Market segmentation by route of administration

  • Oral
  • Parenteral
  • Transdermal

PART 08: Global estrogen replacement therapy market

  • Market overview
  • Market size and forecast

PART 09: Global growth hormone replacement therapy market

  • Market overview
  • Market size and forecast

PART 10: Geographical segmentation

  • Hormone replacement therapy market in Americas
  • Hormone replacement therapy market in EMEA
  • Hormone replacement therapy market in APAC

PART 11: Market drivers

  • Unmet medical needs
  • Advances in technology
  • Reformulation of approved drugs
  • Lifestyle changes

PART 12: Impact of drivers

PART 13: Market challenges

  • High cost of therapy
  • Adverse effects
  • Storage issues
  • Weak pipeline

PART 14: Impact of drivers and challenges

PART 15: Market trends

  • Novel drug delivery mechanisms
  • Paradigm shift toward non-hormonal therapies
  • Mergers and acquisitions

PART 16: Vendor landscape

  • Competitive scenario
  • Key news
  • Mergers and acquisitions
  • Market share analysis 2014
  • Other prominent vendors

PART 17: Key vendor analysis

  • F. Hoffmann-La Roche
  • Merck Serono
  • Novartis
  • Novo Nordisk

PART 18: Appendix

  • List of abbreviation

PART 19: Explore Technavio

List of Exhibits

  • Exhibit 01: Product offerings
  • Exhibit 02: Global hormone replacement therapy market 2014-2019 ($ millions)
  • Exhibit 03: Five forces analysis
  • Exhibit 04: Global hormone replacement therapy market segmentation by type of hormonal therapy, 2014 (%)
  • Exhibit 05: Global hormone replacement therapy market segmentation by type of hormonal therapy 2014-2019 ($ millions)
  • Exhibit 06: Global hormone replacement therapy market by route of administration
  • Exhibit 07: Global estrogen replacement therapy market 2014-2019 ($ millions)
  • Exhibit 08: Global growth hormone replacement therapy market 2014-2019 ($ millions)
  • Exhibit 09: Global hormone replacement therapy market by geography, 2014
  • Exhibit 10: Global hormone replacement therapy market by key geographies, 2014-2019 ($ millions)
  • Exhibit 11: Hormone replacement therapy market in Americas 2014-2019 ($ millions)
  • Exhibit 12: Hormone replacement therapy market in EMEA 2014-2019 ($ millions)
  • Exhibit 13: Hormone replacement therapy market in APAC 2014-2019 ($ millions)
  • Exhibit 14: Impact of drivers
  • Exhibit 15: Impact of drivers and challenges
  • Exhibit 16: Global sales of Nutropin 2012-2014 ($ millions)
  • Exhibit 17: Key takeaways: F. Hoffmann-La Roche
  • Exhibit 18: Global sales of Saizen 2012-2014 ($ millions)
  • Exhibit 19: Global sales of Gonal-f 2012-2014 ($ millions)
  • Exhibit 20: Key takeaways: Merck Serono
  • Exhibit 21: Key takeaways: Novartis
  • Exhibit 22: Global sales of Norditropin 2012-2014 ($ millions)
  • Exhibit 23: Key takeaways: Novo Nordisk
  • Exhibit 24: Global sales of Genotropin 2012-2014 ($ millions)
  • Exhibit 25: Global sales of Premarin 2012-2014 ($ millions)
  • Exhibit 26: Global sales of Depo Provera 2012-2014 ($ millions)
  • Exhibit 27: Key takeaways: Pfizer
  • Exhibit 28: Merck Serono: Product segmentation 2014
  • Exhibit 29: Merck Serono: Geographical segmentation by revenue 2014
  • Exhibit 30: Business segmentation by revenue in percentage, 2014
  • Exhibit 31: Novo Nordisk: Business segmentation by revenue 2013 and 2014
  • Exhibit 32: Novo Nordisk: Geographical segmentation by revenue 2014
  • Exhibit 33: Novo Nordisk: R&D expenditure 2014
Back to Top